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1061-77 Insulin Resistance and Survival in Chronic Heart Failure 
Wolfram Doehner, Ian F. Godsland, Mathias Rauchhaus, Piotr P. Ponikowski, Andrew J. 
Coats, Stefan D. Anker, National Heart & Lung Institute. London, United Kingdom 
Background: Impaired insulin sensitivity (Si) is a feature of chronic heart 
failure (CHF) independently of ischemic etiology. In CHF. impaired Si is 
related to abnormal energy metabolism, decreased exercise capacity and 
muscle fatigue. The relationship between presence of Insulin resistance 
(i.e. low Si) and survival in patients with CHF has not been established. 
Methods: We prospectively studied 105 patients with CHF due to an ischemic 
etiology (64%) or dilated cardiomyopathy (36%). All patients were in stable 
clinical condition and had full conventional medical therapy (mean age 
62+ly, NYHA class 2.6kO.1, BMI 24.7+0.5 kg/m’. LVEF 28+2%, peak VO, 
17.9+0.7 mlikglmin. Si was assessed from glucose and insulin dynamic 
profiles during an intravenous glucose tolerance test using the minlmal 
model technique. 
Results: During a mean follow-up period of 44*4 months, 53 (50%) patients 
died. Cumulative mortality was 20% at 24 months. In univariate Cox 
proportional hazard analysis, low Si predicted Increased mortality (RR 
1.21, p=O.O16). Also age, NYHA class, and peak VO, predicted mortality (all 
pcO.Ol), but LVEF and BMI did not. In multivariate analysis, low Si 
(p<O.Ol) preduzted increased mortality independently of age (pcO.O5), NYHA class 
and peak VO, (both p>O.Z). 
According to median Si (mm.‘.pU.mL-‘.I@), we divided the CHF patients in two 
groups. Patients with Si below median (n=52: mean Si 0.95*0.07 min.’ .pU.ml” .I04) 
had worse survival than patients with Si above median (n=53: mean Si 
4.08+0.40 min.‘.pU.mL-I.104): hazard ratio 2.7 [95% Cl 1.5-4.71, p<O.OlX). Both 
patient groups were similar for age and NYHA (both p>O.3), but patients 
with Si above median had higher LVEF (33*3 vs 24+2%) and peak V@ (19.9*1.0 
vs 16.8*1.0 mUkg/min; both ~~0.05). Patients with Si below median had 
P-year survival of 61% (46-741, but patients with Si above median had 
2-year survival of 63% [73-931 (hazard ratio adjusted for age, NYHA, LVEF. 
and peak VO,: 3.0 [1.5-6.01). 
Conclusion: In patients with CHF, impawed insulin 
sensitivity relates to poor survival, independently of established 
prognosticators. Therapeutically targeting impaired Insulin sensitivity may 
potentially improve prognosis in CHF patients. 
Emergency Depaltment. There were 1,586 patients in the study and 774 (47%) were 
diagnosed with HF. Of these, 634 (82%) had BMI data and were included for this analy- 
sis. 
Results: There was an inverse relationship between BNP levels and BMI in patients with 
HF (table). After accounting for age, sex, NYHA classification (I-IV) and history of HF by 
multiple linear regression analysis there remained a significant werse relationship 
between BNP and BMI ( r =-0.282, pc 0.0001). 
Conclusion: There is an inverse relationship between BNP levels and BMI in patients 
with HF. Improved prognosis m obese HF patients may be due to less ss~ere left ventric- 
ular dysfunction and hemodynamic abnonalities as indkxted by lower BNP concentra- 
tions. This finding may have diagnostic and/or therapeutic implications for obese patients 
with HF. 
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1061-60 Monocyte Chemoattractant Protein-l Plasma Level Is 
Elevated in Patients With Compensated lschemic 
Cardiomyopathy but Not the Tumor Necrosis Factor- 
Alpha 1061-76 Metabolic and Hemodynamic Parameters Do Not 
Predict Sleep Disordered Breathing in Severe Stable 
Heart Failure 
Laurie A. Kilkenny, Srinivas Murali. Guy A. MacGowan. Michael A. Math& Dennis M. 
McNamara, Tammy R. Tokarczyk, Rachel J. Givelber, Patrick J. Strollo, University of 
Pittsburgh, Pittsburgh, PA 
Background: Intermittent hypoxemia associated with sleep disordered breathing (SDB) 
contributes to cardiovascular impairment and may alter prognosis in heart failure (HF). 
We sought to examine the prevalence of SDB and assess whether hemodynamic and 
metabolic parameters would predict SDB I” stable severe HF patients (pts). 
Methods: We studied 22 pts (18M/4F; mean age 55.5 +/- 6.4 years; BMI 29.2+/-6) wth 
NYHA class Ill or IV HF (LVEF I9 +/- 0.05%) on optmal medical therapy (87% on ACE 
inhibitors. 91% on beta blockers) who underwent hemodynamic assessment, cardiopul- 
monary exercise study (modified Naughton protocol), and unattended cardiopulmonary 
slew studv (Stardust TM with nasal pressure). The presence of Central Sleep Apnea- ,~ 
Cheyne-Stokes Respirations (CSA-CSR) and Obstructive sleep dwxdered breathing 
(OSDB) was assessed using apnea hypopnea index, frequency of central and obstruc- 
twe events and duration of hypoxemia. The coefficient of determination (r2) was deter- 
mined by linear regression. 
Results Fifteen pts (68%) had ischemic cardiomyopathy; IO pts (45%) had Paroxysmal 
Nocturnal Dyspnea ; and 9 pts (41%) had Implantable defibrillators. Seven pts (32%) 
were diagnosed with CSA-CSR and I4 pts (64%) with OSDB. For the group. Desatura- 
tion event frequency was 22.4+/- 25.6; Apnea Hypopnea Index 30.9+/-16.7; and Minutes 
02 saturation <90% 42.6 +/- 100.9 minutes. Pulmonary artery wedge pressure (16.8 +/- 
7.2mm Hg); Cardiac Index (2.4 +I- 0.4 llminim2); PA mean pressure (28.3 +/- 11 mmHg); 
mlxed venous 02 saturation (66.2 +/- 5.4%); peak exercise oxygen consumption (16 +I- 
5.8 mllminlkg); and exercise ventilatory equivalent for carbon-dioxide (39.1+/- 11.3) did 
not correlate with the presence of SDB. 
Conclusions: 1) SDB is very common in pts with severe stable HF. 2) The prevalence of 
SDB in our series was 95% with a high proportion of OSDB. 3) No hemodynamic or met- 
abolic parameters correlated with the presence of SDB. 4) Stable severe HF pts should 
be routmely evaluated for the presence of SDB. 
1061-79 B-Type Natriuretic Peptide Levels Are Inversely Related 
to Body Mass Index in Patients With Heart Failure 
Brian J. Mundy, James McCord, Richard M. Nowak, Michael P. Hudson, Barabara 
Czerska, Gordon Jacobsen, Torbjorn Omland, Alan H. Wu, Phillippe Due, Judd E. 
Hollander, Peter A. McCullough, Alan S. Maisel, Henry Ford Hospital, Detroit, Ml 
Background: B-type natriurebc peptide (BNP) is a neurohormone secreted from the 
ventricular myocardium in response to increased wall tension, and is commonly elevated 
I” patients with heart failure (HF). BNP elevation has prognostic significance in patients 
with HF, and obese patients with HF are known to have a better prognosis for unclear 
reasons. We sought to determine the relationship, if any, between BNP levels and body 
mass index (BMI) in patients presenting to the Emergency Department with HF. 
Methods: The BNP Multinational Study was a seven center prospective study that eval- 
uated the diagnostic accuracy of BNP measurement for identifying patients with HF in the 
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Samer J. Khouri, Jeanene Pohorence Ferguson, Laura Yamokoski, Karen Donavan, 
Amy Ferketich, Philip Binkley, Ohio State University, Columbus, OH, Medical College of 
Ohio, Toledo, OH 
Background: Several studies have shown that cytokine plasma levels are elevated in 
patients with decompensated heart failure. The treatment of these patients lead to 
decreased levels of Tumor necrosis Factor-alpha (TNF). A growing body of experimental 
evidence supports the pivotal role of chemokines in the pathogenesis of coronary artery 
disease and cardiomyopathy. The endothelial expression of monocyte chemoanractant 
protein-l (MCP-1) is apparently essential for the earliest cellular responses of atherogen- 
esis. We compared chemokine levels of MCP-I with cytokine levels of TNF in patients 
with compensated ischemic cardiomyopathy (NYHA functional class II & Ill) who were 
treated with B-blockers and ACE-Inhibitors for 3 months or more. 
Methods: MCP-I and TNF levels were obtained from 16 healthy controls and 21 patients 
with ischemic cardiomyopathy using commercially available immunoassays (R&D Sys- 
tem, Minneapolis, MN). The assays used the quantitative sandwich enzyme immunoas- 
say technique. Exact Wilcoxon Rank Sum’tests were performed to compare MCP-I and 
TNF levels between patients and healthy controls. The outcome variables were deter- 
mined from the average of two MCP-1 measurements and two TNF measurements. 
Two-sample nonparametric tests were performed. 
Results: The average MCP-I level among patients was (281.88 + 106.28 ng/ml), 
whereas it was (157.88 + 42.92 ng/ml) among controls (p c 0.00001). The average TNF 
levels among patients were (8.40 * 3.86 pglml) and (7.9 * 2.17 pgiml) among controls 
(NS). Conclusion: MCP-1 continues to be elevated in patients with compensated 
ischemic cardiomyopathy despite the treatments. This study supports previous reports 
that TNF concentration plasma levels in compensated cardiomyopathy will decrease with 
medical treatment. These findings also support the hypotheses that the inflammatory 
process continues despite heart failure treatment with B-blockers and ACE-Inhibitors. 
Therapeutic strategies that block MCP-1 in heart failure pabents provide hope of prevent- 
ing or reversing disease progression. 
1061-81 Redhced Pulmonary Clearance of Endothelin-1 in 
Patients With Congestive Heart Failure 
Cezar Staniloae, Jocelvn Dupuia Gilbert Gosselin. lhor Dyrda, Marc Bois. Jacques 
C&pew, Raoul Bonan, Michel White, Alexandre Caron. Montreal Heart Institute, 
Montreal, PQ, Canada 
Background. Endothelin-I (ET-l) levels are increased in patients wth CHF and are 
strong predictors of outcome. The pulmonary circulation plays a major role in the produc- 
tion and removal of ET-l. The endothellal ETB receptor mediates ET-1 clearance and 
causes vasodilation through the release of nitric oxide and prostacyclin. 
Methods. Twenty-five patients with CHF undergoing diagnostic catheterization were 
recruited. A single bolus indicator-dilution experiment was performed by injection into the 
RV outflow tract of a mixture containing 1251.ET-1 and Evans’ blue-labelled albumin, and 
simultaneous collection of timed samples above the aortic valve. Hemodynamic parame- 
ters, ET-1 levels and pulmonary ET-l kinetic data were correlated using a Pearson corre- 
lation matrix. 
